3,4-Dihydroxymethcathinone
 | |
| Clinical data | |
|---|---|
| Other names | HHMC; Dihydroxymethcathinone; 3,4-Dihydroxy-N-methylcathinone; 3,4HO-MC; 3′,4′-Hydroxy-2-(methylamino)propanophenone |
| Drug class | Norepinephrine–dopamine releasing agent |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C10H13NO3 |
| Molar mass | 195.218 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
3,4-Dihydroxymethcathinone (HHMC), or 3,4-dihydroxy-N-methylcathinone, is a monoamine releasing agent of the amphetamine and cathinone families.[1][2] It is an active metabolite of methylone (3,4-methylenedioxymethcathinone; MDMC).[1][2] The drug is a norepinephrine–dopamine releasing agent (NDRA), with EC50 values of 110 nM for norepinephrine, 90 nM for dopamine, and 14,100 nM for serotonin in rat brain synaptosomes.[1][2] HHMC was first described in the scientific literature by 2017.[1][2]
See also
[edit]- 4-Hydroxy-3-methoxymethcathinone (HMMC; 4-HO-3-MeO-MC)
- α-Methyldopamine (3,4-dihydroxyamphetamine; HHA; 3,4-DHA)
- α-Methylepinine (3,4-dihydroxymethamphetamine; HHMA, 3,4-DHMA)
- 4-Hydroxy-3-methoxyamphetamine (HMA)
- 4-Hydroxy-3-methoxymethamphetamine (HMMA)
References
[edit]- ^ a b c d Elmore JS, Dillon-Carter O, Partilla JS, Ellefsen KN, Concheiro M, Suzuki M, et al. (February 2017). "Pharmacokinetic Profiles and Pharmacodynamic Effects for Methylone and Its Metabolites in Rats". Neuropsychopharmacology. 42 (3): 649–660. doi:10.1038/npp.2016.213. PMC 5240186. PMID 27658484.
- ^ a b c d Luethi D, Kolaczynska KE, Walter M, Suzuki M, Rice KC, Blough BE, et al. (July 2019). "Metabolites of the ring-substituted stimulants MDMA, methylone and MDPV differentially affect human monoaminergic systems". Journal of Psychopharmacology. 33 (7): 831–841. doi:10.1177/0269881119844185. PMC 8269116. PMID 31038382.
External links
[edit] | This psychoactive drug-related article is a stub. You can help Wikipedia by expanding it. |